BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/7/2019 4:43:36 AM | Browse: 862 | Download: 1720
 |
Received |
|
2019-06-17 00:25 |
|
Peer-Review Started |
|
2019-06-17 05:55 |
|
To Make the First Decision |
|
2019-07-22 03:28 |
|
Return for Revision |
|
2019-07-24 00:51 |
|
Revised |
|
2019-07-30 06:15 |
|
Second Decision |
|
2019-08-16 09:24 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-08-19 13:32 |
|
Articles in Press |
|
2019-08-19 13:32 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-09-04 03:22 |
|
Publish the Manuscript Online |
|
2019-09-07 04:43 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Won Hyeok Choe, Ki Jeong Kim, So Young Lee, Yu Min Choi, So Young Kwon, Jeong Han Kim and Bum Joon Kim |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Bum Joon Kim, PhD, Professor, Department of Biomedical Sciences, Microbiology and Immunology, Liver Research Institute, Cancer Research Institute and SNUMRC, College of Medicine, Seoul National University, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea. kbumjoon@snu.ac.kr |
| Key Words |
Chronic hepatitis B; Entecavir; Hepatitis B virus; Liver fibrosis; Mutation; Tenofovir |
| Core Tip |
Hepatitis B virus (HBV) DNA polymerase mutations have been known to be prevalent in treatment-naïve chronic hepatitis B (CHB) patients infected with HBV genotype C2 strains. The newly developed locked nucleotide probe based real-time PCR method could discriminate the naturally-occurring rtM204I mutations from wild type with high sensitivity in treatment-naïve patients. Multivariate analyses showed that the naturally-occurring rtM204I variants were more frequently pre-existed in patients with liver fibrosis, and the pre-existence of the naturally-occurring rtM204I variants were significantly associated with incomplete viral response to nucleos(t)ide analogues. Tenofovir is a more suitable nucleos(t)ide analogues than entecavir for treatment-naïve CHB patients carrying the naturally occurring rtM204I mutations. |
| Publish Date |
2019-09-07 04:43 |
| Citation |
Choe WH, Kim KJ, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019;25(33): 4985-4998 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i33/4985.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i33.4985 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
